About avalo therapeutics inc - AVTX
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.
AVTX At a Glance
Avalo Therapeutics, Inc.
1500 Liberty Ridge Drive
Wayne, Pennsylvania 19087
| Phone | 1-410-522-8707 | Revenue | 59.00K | |
| Industry | Pharmaceuticals: Major | Net Income | -78,259,000.00 | |
| Sector | Health Technology | Employees | 33 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
AVTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4,125.961 |
| Price to Book Ratio | 4.048 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.032 |
| Enterprise Value to Sales | 2,499.758 |
| Total Debt to Enterprise Value | 0.016 |
AVTX Efficiency
| Revenue/Employee | 1,787.879 |
| Income Per Employee | -2,371,484.848 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.00 |
AVTX Liquidity
| Current Ratio | 8.136 |
| Quick Ratio | 8.136 |
| Cash Ratio | 7.602 |
AVTX Profitability
| Gross Margin | -483.051 |
| Operating Margin | -123,601.695 |
| Pretax Margin | -132,362.712 |
| Net Margin | -132,642.373 |
| Return on Assets | -58.308 |
| Return on Equity | -72.435 |
| Return on Total Capital | -91.557 |
| Return on Invested Capital | -70.994 |
AVTX Capital Structure
| Total Debt to Total Equity | 2.922 |
| Total Debt to Total Capital | 2.839 |
| Total Debt to Total Assets | 2.062 |
| Long-Term Debt to Equity | 2.45 |
| Long-Term Debt to Total Capital | 2.381 |